Abstract: The present invention relates to an electromagnetic flowmeter. The present invention provides an electromagnetic flowmeter for measuring flow of fluid flowing in a conduit of the electromagnetic flowmeter, wherein the electromagnetic flowmeter comprises: a pair of electrodes mounted on the conduit for measuring potential difference generated by the interaction of electromagnetic field in the fluid to determine the flow of fluid in the electromagnetic flowmeter; a processing unit, wherein the processing unit acquires signals from the pair of electrodes and processes the signal for measurement, a set of coils comprising at least two coils mounted on a surface of the conduit and excited by an excitation unit for generating an electromagnetic field, wherein a first coil from the set of coils is concentrically positioned with a second coil from the set of coil, and the second coil is placed within the enclosed surface area of the first coil.

Abstract: There are provided antibodies and combination thereof, and other binding proteins against malarial antigens, as well as said antigens and vectors encoding the antibodies and antigens. The invention also provides the use of such compounds and combinations thereof in the prevention or treatment of malaria. In particular, synergistic combinations of non-neutralising antibodies directed towards an epitope on Reticulocyte-binding protein Homologue 5 (PfRH5) and neutralising antibodies directed towards Plasmodium merozoite antigens are provided.

Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising fragments of Reticulocyte-binding protein Homologue 5 (PfRH5). In particular, the invention provides fragments of PfRH5 rationally designed on the basis of the PfRH5 crystal structure, wherein said fragments which lack disordered regions, particularly the flexible N-terminal region and/or flexible central linker.

Abstract: The present invention relates to an electromagnetic flowmeter. The present invention provides an electromagnetic flowmeter for measuring flow of fluid flowing in a conduit of the electromagnetic flowmeter, wherein the electromagnetic flowmeter comprises: a pair of electrodes mounted on the conduit for measuring potential difference generated by the interaction of electromagnetic field in the fluid to determine the flow of fluid in the electromagnetic flowmeter; a processing unit, wherein the processing unit acquires signals from the pair of electrodes and processes the signal for measurement, a set of coils comprising at least two coils mounted on a surface of the conduit and excited by an excitation unit for generating an electromagnetic field, wherein a first coil from the set of coils is concentrically positioned with a second coil from the set of coil, and the second coil is placed within the enclosed surface area of the first coil.

Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.

Abstract: Methods and apparatus are for storing and retrieving data related to the installation, service, repair or performance of an industrial flow meter or other measurement instrument. Methods and apparatus are also for other processes associated with measurement instruments.

Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising fragments of Reticulocyte-binding protein Homologue 5 (PfRH5). In particular, the invention provides fragments of PfRH5 rationally designed on the basis of the PfRH5 crystal structure, wherein said fragments which lack disordered regions, particularly the flexible N-terminal region and/or flexible central linker.

Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.

Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.

Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.

Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumour antigen for use as a medicament.

Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.

Abstract: An industrial meter has wireless communication circuitry for communicating with a remote communication device. A repeater device allows the wireless communication circuitry of the industrial meter to continue to communicate with the remote communication device when the meter device is positioned in a location where direct communication between the wireless communication circuitry and the remote communication device is not possible (such as for example when the industrial meter is located underground).

Abstract: Methods and apparatus are for storing and retrieving data related to the installation, service, repair or performance of an industrial flow meter or other measurement instrument. Methods and apparatus are also for other processes associated with measurement instruments.

Abstract: There is provided a composition comprising: (a) a modified vaccinia virus ankara (MVA) vector, wherein said MVA vector comprises a nucleic acid sequence encoding an antigen; and (b) an adjuvant comprising a saponin, or an emulsion. There is also provided a composition comprising: (a) an adenovirus vector, wherein said adenovirus vector comprises a nucleic acid sequence encoding an antigen, and wherein the adenovirus is selected from: a group B adenovirus, a group C adenovirus, and a group E adenovirus; and (b) an adjuvant comprising a saponin, or an emulsion; wherein the group B adenovirus is not an adenovirus 35, the group C adenovirus is not Ad5 having an intact E3 gene region, and the group E adenovirus is not an adenovirus C7. Also provided are corresponding uses of the compositions in medicine.

Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.

Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumour antigen for use as a medicament.

Abstract: An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest.